Clicky

TCR2 Therapeutics Inc.(TCRR)

Description: TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company's lead product candidates include TC-210, mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which initiated in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies. Its product candidates in pipeline focuses on adult acute lymphoblastic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma areas. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.


Keywords: Medicine Cancer Clinical Medicine Solid Tumors Immunotherapy Cancer Immunotherapy Lymphoma Non Small Cell Lung Cancer Ovarian Cancer Small Cell Lung Cancer Proteins Carcinoma Treatment Of Non Small Cell Lung Cancer Hematological Malignancies Nsclc Acute Lymphoblastic Leukemia Mesothelioma Tumors Of The Hematopoietic And Lymphoid Tissues CD19 Cholangiocarcinoma Helio Immunogen Follicular Lymphoma Diffuse Large B Cell Lymphoma Mesothelin Positive Solid Tumors

Home Page: www.tcr2.com

TCRR Technical Analysis

100 Binney Street
Cambridge, MA 02142
United States
Phone: 617 949 5200


Officers

Name Title
Dr. Garry E. Menzel M.B.A., Ph.D. Pres, CEO & Director
Dr. Patrick A. Baeuerle Ph.D. Founder & Member of the Advisory Board
Mr. Peter Olagunju Chief Technical Officer
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer
Mr. Richard Roomberg VP of Corp. Controller
Mr. Eric M. Sullivan CPA Chief Financial Officer
Carl Mauch Sr. Director of Investor Relations & Corp. Communications
Ms. Margaret Siegel J.D. Head of Legal & Corp. Sec.
Dr. Angela Justice Ph.D. Chief People Officer
Dr. Rosemary Harrison Ph.D. Chief Bus. & Strategy Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.222
Price-to-Sales TTM: 0
IPO Date: 2019-02-14
Fiscal Year End: December
Full Time Employees: 105
Back to stocks